top of page
Writer's picturePrateek Baranwal

Breast Implant Market will be US$ 4.45 Billion by 2032


Global Breast Implant Market Analysis 

The breast Implant Market is projected to grow to US$ 4.45 billion by 2032 from US$ 2.32 billion in 2023, growing at a CAGR of 7.5% from 2024 to 2032.

Breast enlargement, also known as breast augmentation, involves placing an implant under the breast tissue to increase its size and shape. The implants can be inserted through incisions under the breast, in the armpit, or around the nipple. They can be positioned directly behind the breast, on top of the chest wall muscle, or behind the breast and chest wall muscle (sub-muscular). Breast implants are used for augmentation, reconstruction, and to improve the appearance of the breasts.

 

Growth Driver of the Breast Implant Market

Rising demand for cosmetic procedures worldwide: The rising demand for cosmetic procedures worldwide reflects a growing trend of people seeking to enhance their appearance, driven by technological advancements, changing beauty standards, and a desire for self-improvement. As the stigma diminishes, more individuals opt for these treatments to feel more confident and comfortable. Breast implantation surgery has advanced significantly due to the growing demand, with many women contributing to the market's growth. According to FDA guidelines, women over 18 are eligible for breast augmentation surgeries. In India, there are over 10,000 breast implantation procedures performed each year, while globally, the number of augmentation procedures surpassed 1.6 million in 2023, making it one of the most prevalent cosmetic surgeries worldwide.

 

Request a free sample copy of the report: https://www.renub.com/breast-implant-market-p.php

 

Growing incidence of breast cancer: The growing incidence of breast cancer is a concerning trend that requires increased awareness, research, and access to healthcare resources. The breast implant market is expanding due to the increasing prevalence of breast cancer. In severe cases, preventing this disease may require mastectomy surgery, which involves the removal of the entire organ. Reconstruction of the organ is a valuable option for treating such disease, involving reshaping the removed organ. In 2022, 2.3 million women were diagnosed with breast cancer, resulting in 670,000 deaths worldwide. It is estimated that in 2023, the number of new cases was 2,97,790 of invasive breast cancer will be diagnosed in U.S. women, along with 55,720 new cases of DCIS. As the number of reconstruction cases rises, there is an increasing demand for breast implantation over the forecast period.

Advancements in Implant Technology: The advancements in implant technology have revolutionized medical treatment, providing more precise and effective solutions for various health conditions. It mentions that market players are constantly developing better and more efficient solutions and improving the quality of available products through multiple strategies such as awareness campaigns, product launches, collaborations, and mergers and acquisitions to support market growth. In June 2023, VSS Capital Partners, an investment firm focusing on healthcare, education, and business services, announced an investment in Olympus Cosmetic Group, a new platform offering comprehensive cosmetic surgery, dermatological treatments, and non-surgical cosmetic procedures. The introduction of advanced breast implants is expected to contribute to the market's growth. 

 

North America Breast Implant Market 

The North American breast implant market is experiencing steady growth, driven by main factors such as increasing awareness, technological advancements, rising disposable income, and the increasing emphasis on physical appearance and aesthetics. The market is significant, with the United States poised to dominate due to the high demand for cosmetic surgeries, particularly breast augmentation. This trend highlights potential growth and investment opportunities in the region.

In the US, Breast cancer accounts for about more than 30% of all new female cancer cases annually, with an estimated 297,790 new cases of invasive breast cancer and 55,720 new cases of DCIS diagnosed in 2023 in the US. In 2022, 28,600 Canadian women were diagnosed with breast cancer, making up 25% of all new cancer cases in women in Canada.

In October 2022, the American College of Radiology launched a significant collaboration with the Breast Cancer Research Foundation and GE Healthcare. Simultaneously, the University of Texas MD Anderson Cancer Center and the World Health Organization (WHO) formed an international partnership to tackle the widespread global effects of women's cancers.

 

Breast Implant Company Analysis: 

Some major companies are present in the global breast implant industry. These are Abbvie Inc., Sientra Inc., Hans Biomed Co., Ltd, Establishment Labs SA, Guangzhou Wanhe Plastic Materials Co., Ideal Implant Inc., Laboratoires Arion, Polytech Health & Aesthetics GmbH, Mentor Worldwide LLC and Sebbin.

 

Breast Implant Company News: 

June 2023: Olympus Cosmetic Group, a recently established platform offering comprehensive cosmetic surgery, dermatological treatments, and non-surgical cosmetic procedures, recently received an investment from VSS Capital Partners.

November 2023: Allergan Aesthetics, an AbbVie subsidiary, acknowledges the enormously personal choice that patients experience when selecting breast surgery. The new Natrelle® campaign, "For Every BODY," celebrates patients and their stories using new imagery and visual assets. The campaign illustrates how any curve, shape, and BODY can have a personalized look with the Natrelle® breast implant collection.  

October 2022: GC Anesthetics received CE approval for the micro-textured anatomical breast implant LUNA tx, allowed under the new European Medical Device Regulation (MDR).  

June 2022: To meet breast reconstruction needs, Coll Plant announced the commencement of research in large animals for its 3D bio-printed regenerative breast implant program.

January 2022: The FDA has approved Mentor Worldwide LLC's MENTO MemoryGel BOOST breast implant for breast augmentation in women 22 and older.  

 


Product– Market breakup in 2 viewpoints:

 

1.       Silicone Implants

2.       Saline Implants

 

 

Shape - Market breakup in 2 viewpoints:

 

1.       Round

2.       Anatomical

 

 

Application- Market breakup in 2 viewpoints:

 

1.       Breast Cosmetic Surgery

2.       Breast Reconstruction Surgery

 

 

End User- Market breakup in 2 viewpoints:

 

1.       Hospitals

2.       Cosmetology Clinics

 

 

Country – Market breakup of 17 Countries:

 

1.       United States

2.       Brazil

3.       Japan

4.       Mexico

5.       Turkey

6.       Germany

7.       Argentina

8.       Italy

9.       Colombia

10.   India

11.   Spain

12.   Greece

13.   Iran

14.   Romania

15.   United Kingdom

16.   Thailand

17.   Rest of the world

 

 

All the key players have been covered from 4 Viewpoints:

 

·         Business Overview

·         Product Portfolio

·         Recent Development & Strategies

·         Revenue Analysis

 

 

Key Players Analysis:

 

1.       Abbvie

2.       Sientra Inc.,

3.       Hans Biomed Co., Ltd

4.       Establishment Labs SA

5.       Guangzhou Wanhe Plastic Materials Co.

6.       Ideal Implant Inc.

7.       Laboratoires Arion

8.       Polytech Health & Aesthetics GmbH

9.       Mentor Worldwide LLCs

10.   Sebbin



Related Reports




About the Company:

Renub Research is a Market Research and Information Analysis company with more than 15 years of experience in Research, Survey, and Consulting. Our research helps companies to take business decisions: on strategy, organization, operations, technology, mergers & acquisitions, etc. Till now we have published more than 9000 syndicated reports and worked on more than 750 custom research projects. Currently, we are supplying data to EMIS, Bloomberg, Thomson Reuters, etc. We support many blue-chip companies by providing them with findings and perspectives across a wide range of markets.

 

Contact Us:

Renub Research

Phone No: +1-478-202-3244 | +91-120-421-9822 (IND)

Comments


bottom of page